

Institute of
High Performance
Computing
IHPC
































4\$5-6*.-#"-1"(6



! "#\$%&%

...AGCAAAAGCAGGGGAAAACAAAAGCAACAAAAATGAAGGC AATACTAGTAGTTCTGCTATATACATTTGCAACCGCAAATGCA GACACATTATGTATAGGTTATCATGCGAACAAT ACAGACA CTGTAGACACAGTACTAGAAAAGAATGTAACAGTAACACACTC TGTTAACCTTCTAGAAGACAAGCATAACGGGAAACTATGCA...

/#()\$01*2-+&13






















4\$5-6*.-#"-1"(6



...AGCAAAAGCAGGGGAAAACAAAAGCAACAAAAATGAAGGC AATACTAGTAGTTCTGCTATATACATTTGCAACCGCAAATGCA GACACATTATGTATAGGTTATCATGCGAACAAT ACAGACA CTGTAGACACAGTACTAGAAAAGAATGTAACAGTAACACACTC TGTTAACCTTCTAGAAGACAAGCATAACGGGAAACTATGCA...













Computational prediction of protein allergenicity potential: AllerCatPro



!"#\$\%'(\)\$





AllerCatPro predicts if a protein is similar to known allergens





?6)#&-% ! -09"



7%"68*19&*5 (%1*0(5: #&9&6%". &*) -1-%&1%*(+*#&,"-; ,&*: #(1&"6%* $-\%(0"-1\&)^* < "19^* - ,, \&\#8\&6"0"13^*" = \&=^*56787 + \$1''\&-() + '^* - 19 -) 46+:; <+$ *'' =+' **-19-)(/+\$1''&-()4+')0+:; >+' %&''(##%)-+' **-19-)4?

What's new in AllerCatPro





C&% | &E'E"#"1",&' !" #\$% &()*+\$, -. /0)*1. //-)* 23-45678)*


! "#\$%&'(!)'*+#,-!.)'./O1/23#1453'6)'.724,48.)'9%+: %+/;<'9=)'(4#+%+>?,+73?@ABCBBD@ 8EE%+F4,G+7 B@CH'4'I %: 'J%+1%+'K7+'2+%5/; ,/&'''2+7,%/&'4EE%+''%&/;/,\$'27,%&,/4E@! ''#\$%&#'(#&)*'+%*@ @2A*/-#16&#%9": *?8#&&5&61*(6* 20"&61"+"0*2&#. "0&%*%"60&*BC*' &; =BDBE




!-09" F9"5(?6)#&-%



Compiled all known fish allergens from the four most common and well-known allergen databases (n=79)







Created in 2022

- C G6*19&*+\$1\$#&H*I #&,-1". &*"61&6%"13*(+*G8J*; "6)"68*(+*: -#. -,; \$5"6*(+*KB*%: &0"&%* (+*+"%9*0-6*; &*-))&)*1(*: 93,(8&6&1"0*1#&&*"6*(#)&#*1(*: #&)"01*0#(%%L#&-01". "13=
- C '-5",3L






















(422/&"'7K""%&%,/;'
14+/4,/7&'54,4',7'
2+7,%/&'J,+#;,#+%J'4&5'
J%L#%&;%J




!"#\$\\&\'()*+,--.\/0,1\/234



!"#\$\&\'()*+0./3/0,.*\&45*0,45

```
Y2&. &#-, : -1"&61% & 1#&-1&) <"19 0,(: ") (8#&, )") 6(1 #&%: (6) 1( "1H -#& 19&#& -63 0(55(6 5$1-1"(6% "6 19& : (: $,-1"(6 19-1 0($,) -++&01 )#$8 #&%: (6% 9&60& -,,(<"68 5& 1( %1#-1"+3 < 9( %9($,) 8&1 19"% )#$8ZY
```




























3/41/,350. 673/41/873/9

sample D.	age (vaccine status	patient sta	tus drug foldc	barige: H	III THE
sample1	45	icu	1-21	0.2	25
3 sample2	38	HOU!	Si .	0.7	1.23
sample3	3.0	,	Ţ	4.3	25
5_ sample4	27	TOU	J.	1.5	
sample5	57.	iiduk	Ï		1:22
sample6	97.		i i	1.87	
144 20					

\$.1/:/1/,350.614;<=4;<>4#"9

! 7%&#*\$:,(-)*%&^\$&60"68*+-%1-*+",&%*-6)*5&1-)-1-*+",&%U"6*1%._0%._`%(6*+(#5-1%W*"6*19&*,-6)"68* :-8&=*



+&"1*2. (5/68/6%1&"(3*%&0(#. (6%&"(%6@@/2&0(A&1*0*1*0

O&<\frac{H}^*\frac{6}{6}:\frac{4}{8}:\frac{-\pi-1\frac{1}{6}}{6}

S@+, &1%/&%1-+0)&-1'/&(")4

!"#\$%&#' %\$

	&. "!?. ' ?@; . @	A25B' ?@; . @
N+#'''+%J/J,4&;%	В	С
6/+#E%&;%	MW	Υ
8&,/''%&/;'5+/K,'\'%J;42%'O#,4&,	Z	С
U7J,'J2%;/K/;/,\$';34&''%\J3/K,	С	ZY
],3%+'A%&-\$O%'4;,/1/,\$)'4KK%;,J'2+7,%/&' 4;;#O#E4,/7&\J,4:/E/,\$\K#&;,/7&D	0^	M^
1#1/0,051. @/1?@. ,. ''1@5. 4,	C)	DC

?#\$5.&'#E1++9\$&/b*)H+#25#\$'"#\$ 71'").-\$E.)=\$Y.(5(*&'(*5\$&*2\$41K = (''(*5\$+&K).&').(#-\$)E\$-#P1#*/#\$2&'&\$) *\$H''(/''\$'''#\$&*&+9-(-\$(-\$K&-#2\$ 37508 - 2023 | Terrisca Use | Privary Native | Contest TRISAIN Spino 2022 | Teras of Use | Palvacy Notice | Contact

Institute of
